Azvudine - Wikipedia
Azvudine is an antiviral drug which acts as a reverse transcriptase inhibitor. [3] It was discovered for the treatment of hepatitis C [4] and has since been investigated for use against other viral diseases such as AIDS and COVID-19, [2] [5] for which it was granted conditional approval in China. [6] [7] Azvudine was first discovered in 2007. [8]
Oral Azvudine for hospitalised patients with COVID-19 and pre …
A randomized, open-label, controlled clinical trial of Azvudine tablets in the treatment of mild and common COVID-19, a pilot study
A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets ...
Thus, this randomized, open-label, controlled clinical trial (ChiCTR2000029853) was performed in China. A total of 20 mild and common COVID-19 patients were enrolled and randomly assigned to receive azvudine and symptomatic treatment (FNC group), or standard antiviral and symptomatic treatment (control group).
Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in …
2021年12月6日 · Azvudine (FNC) is a nucleoside analog that inhibits HIV-1 RNA-dependent RNA polymerase (RdRp). Recently, we discovered FNC an agent against SARS-CoV-2, and have taken it into Phase III trial for...
Azvudine (FNC): a promising clinical candidate for COVID-19
2020年10月10日 · To evaluate the efficacy and safety of FNC in patients with mild and common COVID-19, we recently conducted a randomized, open-label, controlled clinical trial of FNC tablets in China ...
China approves first homegrown COVID antiviral - Nature
2022年7月26日 · China’s drug regulator granted conditional approval on Monday for an HIV drug to be used to treat COVID-19. The drug, Azvudine, developed by Chinese drugmaker Genuine Biotech, is the first oral...
A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets ...
2020年8月13日 · This pilot study is a randomized, open, controlled clinical trial to evaluate the efficacy and safety of azvudine tablets in the treatment of COVID‐19. Our trial found that azvudine may shorten the time of nucleic acid negativity conversion of persistent mild and common COVID‐19 patient versus standard antiviral therapy.
Efficacy and safety of azvudine in patients with COVID-19: A …
2023年9月14日 · Azvudine can significantly increase the proportion of patients with improved clinical symptoms of COVID-19 within 5 days of treatment and achieve excellent clinical results. In terms of inhibiting COVID-19, it can inhibit the activity of COVID-19 and increase the proportion of PT-PCR negativity.
The first Chinese oral anti-COVID-19 drug Azvudine launched
2022年11月8日 · Remdesivir (Veklury), a broad-spectrum antiviral agent, is the first FDA-approved drug for hospitalized adults with COVID-19. Remdesivir shows superiority to placebo in shortening the recovery time and reduces respiratory tract infection.
A Nearly 20‐Year Journey to Success of Azvudine for Antiviral …
2023年8月15日 · Azvudine is capable of inhibiting SARS-CoV-2, as well as its variants, including Alpha, Beta, Delta, and Omicron. Clinical trials have revealed its real-world effectiveness among hospitalized severely or critically ill COVID-19 patients or those with pre-existing conditions.